The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Garg Pushkal since 2023.
This trader's CIK number is 1829252.
At the time of last reporting, Garg Pushkal was the EVP Chief R&D of Alnylam Pharmaceuticals, Inc.. (stock ticker symbol ALNY).
Also see all insider trading activities at Alnylam Pharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | ALNY | 0 | $0 | 68,701 | $20,001,250 | 56,229 | $4,577,407 |
| 2024 | ALNY | 0 | $0 | 7,419 | $1,628,061 | 1,908 | $0 |
| 2023 | ALNY | 0 | $0 | 29,993 | $5,876,101 | 5,000 | $482,250 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-18 | ALNY | Sale | 1,396 | 452.31 | 631,423 |
| 2025-08-19 | ALNY | Sale | 1,455 | 458.88 | 667,670 |
| 2025-03-24 | ALNY | Sale | 5,445 | 300.00 | 1,633,500 |
| 2025-03-21 | ALNY | Sale | 4,321 | 285.00 | 1,231,485 |
| 2025-03-24 | ALNY | Option Ex | 5,445 | 42.22 | 229,887 |
| 2025-03-04 | ALNY | Sale | 808 | 241.12 | 194,823 |
| 2025-03-03 | ALNY | Sale | 1,749 | 245.04 | 428,571 |
| 2025-02-28 | ALNY | Sale | 935 | 240.70 | 225,058 |
| 2025-02-27 | ALNY | Option Ex | 1,908 | .00 | 0 |
| 2025-01-27 | ALNY | Option Ex | 48,876 | 88.95 | 4,347,520 |
| 2025-01-27 | ALNY | Sale | 52,592 | 285.00 | 14,988,720 |
| 2024-12-12 | ALNY | Sale | 1,752 | 251.62 | 440,838 |
| 2024-11-26 | ALNY | Sale | 1,682 | 250.35 | 421,085 |
| 2024-06-25 | ALNY | Sale | 2,103 | 229.42 | 482,472 |
| 2024-02-27 | ALNY | Option Ex | 1,908 | .00 | 0 |
| 2024-02-28 | ALNY | Sale | 574 | 156.35 | 89,746 |
| 2024-02-16 | ALNY | Sale | 1,308 | 148.26 | 193,920 |
| 2023-08-07 | ALNY | Sale | 4,166 | 184.52 | 768,697 |
| 2023-08-04 | ALNY | Sale | 3,461 | 186.95 | 647,040 |
| 2023-04-27 | ALNY | Sale | 1,839 | 194.96 | 358,524 |
| 2023-04-28 | ALNY | Sale | 2,455 | 198.55 | 487,440 |
| 2023-03-03 | ALNY | Option Ex | 5,000 | 96.45 | 482,250 |
| 2023-03-03 | ALNY | Sale | 18,072 | 200.00 | 3,614,400 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Garg Pushkal (EVP Chief R&D of Alnylam Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.